Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totaling 26,663 shares, a drop of 52.9% from the April 30th total of 56,618 shares. Based on an average trading volume of 79,808 shares, the short-interest ratio is presently 0.3 days. Approximately 0.9% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. 75.62% of the stock is owned by hedge funds and other institutional investors.

Cyclerion Therapeutics Trading Down 0.9%

CYCN traded down $0.03 during trading on Friday, reaching $3.15. 35,107 shares of the company were exchanged, compared to its average volume of 58,116. The stock has a market cap of $13.64 million, a P/E ratio of -2.32 and a beta of 1.80. The firm has a 50 day moving average of $3.03 and a 200 day moving average of $1.99. Cyclerion Therapeutics has a 52 week low of $1.03 and a 52 week high of $8.48.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($17.20) by $16.44. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%. As a group, analysts forecast that Cyclerion Therapeutics will post -1.2 earnings per share for the current fiscal year.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.